Aquestive Therapeutics, Inc. (AQST) 2024 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and welcome to the Aquestive Therapeutics third quarter 2024 conference call. (Operator Instructions)

    早安,歡迎參加 Aquestive Therapeutics 2024 年第三季財報電話會議。(接線員指示)

  • As a reminder, this call will be recorded. I would now like to introduce your host for today's conference call Bennett Watson of ICR Westwicke Investor Relations. You may begin.

    提醒各位,本次電話會議將會錄音。現在我想介紹今天電話會議的主持人:ICR Westwicke 投資人關係部的 Bennett Watson。您可以開始了。

  • Bennett Watson - Investor Relations

    Bennett Watson - Investor Relations

  • Thank you, operator. Good morning, and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer, and Ernie Toth, Chief Financial Officer. We're going to provide an overview of recent business developments and performance for the third quarter of 2024, followed by a Q&A session.

    謝謝,接線員。早安,歡迎各位參加今天的電話會議。今天與我一同出席的有執行長 Dan Barber 以及財務長 Ernie Toth。我們將先概述近期業務進展與 2024 年第三季的營運表現,接著進行問答環節。

  • During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; Dr. Steve Wargacki, Chief Science Officer; and Sherry Korczynski, Senior Vice President of Sales and Marketing. As a reminder, the company's remarks today correspond with the earnings release that was issued after market closed yesterday. In addition, A recording of today's call will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call.

    在問答環節中,團隊也將由醫務長 Carl Kraus 醫師、科學長 Steve Wargacki 醫師,以及銷售與行銷資深副總裁 Sherry Korczynski 一同參與。提醒各位,公司今天的發言內容與昨日收盤後發布的財報新聞稿相對應。此外,今天電話會議的錄音將於本次會議結束後不久,於 Aquestive 官網「投資人」專區提供。

  • To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of a review of third quarter 2024 results. A description of these measures, along with a reconciliation to GAAP can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website.

    提醒各位,今天上午在回顧 2024 年第三季業績時,Aquestive 團隊將討論部分非 GAAP 財務衡量指標。這些指標的說明以及與 GAAP 的調節表,可見於昨日發布並張貼於 Aquestive 官網「投資人」專區的財報新聞稿。

  • During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release as well as the risks and uncertainties affecting the company as described in the Risk Factors section and in other sections included in the company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2024.

    在本次電話會議中,公司將作出前瞻性陳述。我們提醒各位注意公司在昨日財報新聞稿中所載的「安全港」聲明,以及公司於 2024 年 11 月 4 日向美國證券交易委員會提交之 Form 10-Q 季報中「風險因素」章節及其他章節所描述、可能影響公司的風險與不確定性。

  • As with any pharmaceutical company with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval and commercialization of its products and other matters related to operations. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements.

    如同任何擁有研發中產品候選藥物及正在商業化產品的製藥公司,公司在業務、產品研發、監管核准與商業化,以及其他與營運相關事項方面,均面臨重大風險與不確定性。鑑於這些不確定性,您不應過度依賴這些前瞻性陳述;其僅反映作出陳述當日之情況。實際結果可能與這些陳述存在重大差異。

  • All forward-looking statements attributable to Aquestive or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday. The company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law.

    所有可歸因於 Aquestive 或任何代表其行事之人士的前瞻性陳述,均在其整體範圍內明確受本項警示聲明以及昨日發布之財報新聞稿中所載警示聲明的限制。除非適用法律另有要求,公司不承擔在本次電話會議日期之後因新資訊、未來事件或其他原因而更新其前瞻性陳述之義務。

  • With that, I will now turn the line over to Dan.

    接下來,我把電話交給 Dan。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thank you, Bennett. Good morning, everyone, and thank you for joining us today. I am pleased to say that we have once again made tremendous progress since our last earnings call in early August. This is truly an exciting time for the Aquestive team.

    謝謝你,Bennett。各位早安,感謝今天加入我們。我很高興地表示,自 8 月初上次財報電話會議以來,我們再次取得了巨大的進展。對 Aquestive 團隊而言,這確實是一個令人振奮的時刻。

  • In the last three months, we have announced a major new product candidate from our Adrenaverse pipeline program with AQST-108 for alopecia areata, expanded our Libervant launch in the two to five year-old space by adding retail distribution and a full sales team, completed what we believe to be our final adult study for our Anaphylm program and submitted our pre-NDA briefing book to the FDA in anticipation of a fourth quarter pre-NDA meeting. We believe this work has set us up well for continued progress in 2025 and beyond.

    在過去三個月,我們宣布了 Adrenaverse 研發管線計畫中的一項重要新產品候選藥物 AQST-108,用於治療圓形禿;透過新增零售通路與完整銷售團隊,擴大 Libervant 在 2 至 5 歲族群的上市推廣;完成我們認為是 Anaphylm 計畫的最後一項成人研究;並已向 FDA 提交 pre-NDA 簡報資料(briefing book),以準備於第四季召開 pre-NDA 會議。我們相信,這些工作已為我們在 2025 年及更長遠的持續進展奠定良好基礎。

  • Now let's focus on Anaphylm. We recently announced the top line results from our oral allergy syndrome challenge study, which we refer to as our OASIS study. The OASIS study was requested by the FDA to provide clinical data showing that epinephrine plasma concentrations following dosing of Anaphylm are similar with and without the presence of an allergen. As you have seen from our reported results, we have confirmed that the absorption profile of Anaphylm remains the same whether subjects have been exposed to an allergen or not. Importantly, the most meaningful part of this study was our symptom resolution data.

    現在讓我們聚焦於 Anaphylm。我們近期公布了口腔過敏症候群(oral allergy syndrome)誘發試驗的主要結果,我們稱之為 OASIS 研究。OASIS 研究是 FDA 要求進行,以提供臨床數據,證明在使用 Anaphylm 給藥後,腎上腺素的血漿濃度在有無過敏原存在的情況下相近。如各位從我們公布的結果所見,我們已確認:不論受試者是否暴露於過敏原,Anaphylm 的吸收曲線皆維持一致。重要的是,本研究最具意義的部分是我們的症狀緩解數據。

  • During the OASIS study, we tracked the time to symptom resolution without Anaphylm administration and with Anaphylm administration. As a reminder, symptoms included swelling of the lips, tongue and throat along with nasal congestion and systemic symptoms, such as GI tract discomfort as well as tingling. When no Anaphylm was administered, the median time to full symptom resolution was 74 minutes. When Anaphylm was administered, this dropped to 12 minutes. In fact, there are three numbers that resonate with me from this study, 2, 5 and 12. The data showed that subjects started seeing symptom resolution two minutes after the administration of Anaphylm. All swelling symptoms were resolved within five minutes and median time to full symptom resolution was 12 minutes. These are truly remarkable results that make us wonder if treating at the site of symptoms may bring additional benefit to patients. This is something we hope to understand more as we continue to progress.

    在 OASIS 研究期間,我們追蹤了未使用 Anaphylm 與使用 Anaphylm 兩種情況下,症狀緩解所需的時間。提醒各位,症狀包括嘴唇、舌頭與喉嚨腫脹,以及鼻塞與全身性症狀,例如腸胃道不適與刺麻感。在未給予 Anaphylm 的情況下,症狀完全緩解的中位時間為 74 分鐘。在給予 Anaphylm 後,中位時間降至 12 分鐘。事實上,這項研究中有三個數字讓我印象深刻:2、5、12。數據顯示,受試者在使用 Anaphylm 後 2 分鐘即開始出現症狀緩解。所有腫脹症狀在 5 分鐘內解除,而症狀完全緩解的中位時間為 12 分鐘。這些結果確實非常顯著,讓我們思考:在症狀發生部位進行治療,是否可能為患者帶來額外效益。這也是我們在持續推進過程中希望進一步理解的方向。

  • One of the questions that we have heard from the allergy community is how to correlate this data to anaphylaxis. I have discussed this with our medical experts, and we believe that it is important to note the systemic symptoms from our OASIS study, as well as the fact that up to 10% of OAS reactions progress into more severe allergic reactions with up to 2% resulting in anaphylaxis. This gives us confidence that the OASIS study increases our understanding of how Anaphylm works in the presence of edema.

    我們從過敏領域社群聽到的一個問題是:如何將這些數據與過敏性休克(anaphylaxis)做關聯。我已與我們的醫學專家討論過,我們認為需要注意的是:OASIS 研究中的全身性症狀,以及多達 10% 的 OAS 反應會進展為更嚴重的過敏反應,其中多達 2% 會導致過敏性休克。這讓我們更有信心,OASIS 研究提升了我們對 Anaphylm 在水腫存在情況下如何發揮作用的理解。

  • I am also excited to announce today that we received the first part of feedback from our FDA pre-NDA process. We had previously submitted our chemistry, manufacturing and controls pre-NDA questions to the FDA. We recently received a written response from the FDA on all our questions, and I am pleased to say we found the FDA's responses supportive of filing our application.

    我也很興奮地在今天宣布,我們已收到 FDA pre-NDA 流程的第一部分回饋。我們先前已向 FDA 提交化學、製造與管制(CMC)的 pre-NDA 問題。我們近期收到 FDA 對所有問題的書面回覆,我很高興地表示,我們認為 FDA 的回覆支持我們提交申請。

  • I am also pleased to confirm that we have submitted our Anaphylm film clinical briefing book to the FDA for review ahead of our pre-NDA meeting. While we are not disclosing the specific date of the meeting, we remain on track to complete this meeting before the end of the year. We plan on sharing our findings from this meeting once we have final FDA meeting minutes, if not sooner.

    我也很高興確認,我們已將 Anaphylm 薄膜劑型的臨床簡報資料(clinical briefing book)提交給 FDA,供其在 pre-NDA 會議前審閱。雖然我們不會揭露會議的具體日期,但我們仍按計畫在年底前完成該會議。一旦我們取得 FDA 的正式會議紀要(meeting minutes),若非更早,我們將分享本次會議的重點發現。

  • If the FDA is supportive of our plans for submitting our NDA, then we will immediately start our pediatric pharmacokinetic or PK study. This is a single-dose study in children and adolescents between the ages of approximately 7 to 17 years of age. We expect to enroll between 18 and 24 subjects. This will be a multi-site study and each subject will be administered one dose of Anaphylm. Blood draws will be taken and then the subject will go home. This is a similar study to the one conducted by the recently approved epinephrine nasal spray. Based on the anticipated positive FDA feedback and the expected pace of enrollment in our pediatric study, we continue to plan for a Q1 2025 filing and a Q1 2026 launch of Anaphylm, if approved by the FDA.

    若 FDA 支持我們提交 NDA 的規劃,我們將立即啟動兒科藥物動力學(PK)研究。這是一項單次劑量研究,對象為約 7 至 17 歲的兒童與青少年。我們預期將招募 18 至 24 名受試者。這將是一項多中心研究,每位受試者將接受一劑 Anaphylm。將進行抽血採樣,之後受試者即可返家。這與近期獲核准的腎上腺素鼻噴劑所進行的研究相似。基於預期將獲得正面的 FDA 回饋,以及我們兒科研究預期的招募進度,若獲 FDA 核准,我們仍計畫於 2025 年第一季提交申請,並於 2026 年第一季推出 Anaphylm。

  • Now turning to our commercial capabilities, they continue to grow on a daily basis. Our Libervant launch in the two to five-year-old space has helped us build infrastructure around pharmacovigilance, medical affairs, market access and sales management. This has been particularly helpful when it comes to market access as we know that a successful launch must include quick wins with payers. That is why I am pleased to share with you today that we now have Medicaid coverage of Libervant in all 50 states, and we recently completed agreements with two of the top three PBMs and are in negotiations with the third.

    現在轉向我們的商業化能力,這些能力仍在日益成長。我們在2至5歲族群推出Libervant,協助我們建立起藥物安全監測、醫療事務、市場准入與銷售管理等基礎設施。在市場准入方面,這尤其有幫助,因為我們知道成功的上市必須包含與付款方快速取得初步成果。因此,我很高興今天與各位分享:我們目前已在全美50州取得Libervant的Medicaid保險給付,且近期已與前三大PBM中的兩家完成協議,並正與第三家進行協商。

  • I am also pleased to share that as of the first week of October, Libervant was available through retail distribution on a national basis and we have a dozen sales colleagues spending their days educating physicians on the benefits of Libervant for the indicated patient population. This has resulted in a steady increase in prescriptions between September and October, and we are working hard to continue this trend. We will take these learnings and apply them to our Anaphylm commercial launch, if approved by the FDA. We have continued to increase our non-promotional efforts in the anaphylaxis space. These efforts will be an area of increased focus as we move towards submission of our NDA for Anaphylm.

    我也很高興分享,截至10月第一週,Libervant已透過零售通路在全國範圍供應,我們有一打銷售同仁每天向醫師說明Libervant對核准適應症患者族群的效益。這使得9月至10月間處方量穩定增加,我們正努力延續這一趨勢。若Anaphylm獲FDA核准,我們將把這些經驗應用於Anaphylm的商業化上市。我們也持續加強在過敏性休克領域的非促銷性推廣工作。隨著我們朝Anaphylm的NDA提交邁進,這些工作將成為更重要的重點。

  • Now, let's turn to AQST-108, our epinephrine prodrug topical gel. As you heard during our Investor Day on September 27, we believe that the commercial opportunity for AQST-108 could be equal to or larger than Anaphylm. Our goal for 2025 is to conduct a Phase 2a study that will provide additional clinical data supporting our view on the benefits of AQST-108 for alopecia areata. This week, we submitted our briefing book to the FDA for our pre-IND meeting, and we continue to anticipate concluding this activity before the end of the year. We will then open our IND and begin the Phase 2a study.

    接下來談AQST-108,也就是我們的腎上腺素前驅藥外用凝膠。如同各位在9月27日投資人日所聽到的,我們認為AQST-108的商業機會可能與Anaphylm相當,甚至更大。我們2025年的目標是進行一項第2a期研究,以提供更多臨床數據,支持我們對AQST-108在圓形禿(alopecia areata)治療效益的看法。本週我們已向FDA提交pre-IND會議的簡報資料(briefing book),並仍預期在年底前完成此項工作。之後我們將啟動IND並開始第2a期研究。

  • As a reminder, our initial study will focus on determining if we detect a meaningful change from baseline in the Severity of Alopecia Tool score or SALT score for enrolled subjects. We believe patient unmet needs in alopecia areata remain high, the existing JAK inhibitor treatment products in this space worked systemically and come with a significant black box warning. We anticipate AQST-108 will only be absorbed locally and may provide an opportunity for treatment without the adverse events associated with JAK inhibitors.

    提醒一下,我們的初始研究將聚焦於判定受試者的Severity of Alopecia Tool(SALT)分數相較基線是否出現具意義的變化。我們認為圓形禿患者的未被滿足需求仍然很高,而此領域現有的JAK抑制劑治療產品為全身性作用,且伴隨顯著的黑框警語。我們預期AQST-108僅會局部吸收,並可能提供一種不會出現與JAK抑制劑相關不良事件的治療機會。

  • In conclusion, we continue to focus on growing the company across multiple platforms. This includes continuing to advance Anaphylm towards NDA submission, continuing to grow our Libervant prescriptions in the two to five-year-old space and continuing to advance our AQST-108 program for the treatment of alopecia areata. This truly remains an exciting time for the company, the patients it serves and seeks to serve and all our stakeholders.

    總結而言,我們持續專注於透過多個平台推動公司成長。這包括持續推進Anaphylm朝NDA提交邁進、持續提升Libervant在2至5歲族群的處方量,以及持續推進AQST-108用於治療圓形禿的計畫。對公司、公司所服務並希望服務的患者,以及我們所有利害關係人而言,這確實仍是一個令人振奮的時刻。

  • With that, I will turn the call over to Ernie.

    接下來,我把電話會議交給Ernie。

  • Ernest Toth - Chief Financial Officer, Senior Vice President

    Ernest Toth - Chief Financial Officer, Senior Vice President

  • Thank you, Dan, and good morning, everyone. By now, you have seen our financial results in our earnings release that was issued last evening. As we typically do, we will address most of the discussion related to the third quarter 2024 results in the Q&A.

    謝謝你,Dan,各位早安。截至目前,各位已在昨晚發布的財報新聞稿中看到我們的財務結果。如同我們一貫的做法,與2024年第三季業績相關的大部分討論將在問答環節進行。

  • During the third quarter, we continued to execute on our strategy to support the further development of Anaphylm, our lead product candidate that has no needle, is not a device, is orally administered and is easy to carry. We continued our pre-commercial launch activities for Anaphylm to increase awareness among physicians, payers and the advocacy community. On April 26 of this year, we received approval for Libervant for patients ages between two and five years. We have expanded our launch for this pediatric age group with broadening national retail distribution, expanded insurance coverage and additional commercial infrastructure, including a national sales team of 12 individuals in the third quarter to support the continued growth of this product.

    在第三季,我們持續執行策略,以支持我們主力產品候選藥物Anaphylm的進一步開發;該產品無需針頭、不是裝置、可口服給藥且便於攜帶。我們持續進行Anaphylm的上市前商業化活動,以提升醫師、付款方與倡議社群的認知。今年4月26日,我們取得Libervant用於2至5歲患者的核准。我們透過擴大全國零售通路覆蓋、擴大保險給付,以及增加商業化基礎設施(包括第三季建立由12人組成的全國銷售團隊),來擴大此兒科年齡層的上市推廣,以支持該產品持續成長。

  • Now let's turn to the third quarter results. Total revenues increased to $13.5 million in the third quarter of 2024 from $13 million in the third quarter of 2023. This 4% increase in revenue was primarily driven by an increase in license and royalty revenue due to the recognition of deferred revenue from the termination of a licensing and supply agreement, partially offset by decreases in manufacture and supply revenue. Excluding this one-time recognition of deferred revenue, total revenues decreased by $0.7 million or 5% year-over-year.

    現在我們來看第三季的業績。2024年第三季總營收由2023年第三季的1,300萬美元增加至1,350萬美元。營收增加4%主要是因終止一項授權與供應協議而認列遞延收入,帶動授權與權利金收入增加,但部分被製造與供應收入下降所抵銷。若排除這一次性遞延收入認列,總營收年減70萬美元,或年減5%。

  • Manufacture and supply revenue decreased to $10.7 million in the third quarter of 2024 from $11.4 million in the third quarter of 2023, primarily due to the timing of Suboxone and Sympazan revenues, partially offset by an increase in Ondif revenue. Co-development and research fees in the third quarter 2024 remained relatively unchanged compared to the same period in the prior year.

    製造與供應收入由2023年第三季的1,140萬美元下降至2024年第三季的1,070萬美元,主要由於Suboxone與Sympazan收入認列時點的影響,但部分被Ondif收入增加所抵銷。2024年第三季的共同開發與研究費用與去年同期相比大致持平。

  • Total revenues increased to $45.7 million for the nine months ended September 30, 2024, from $37.4 million for the nine months ended September 30, 2023. This 22% increase in revenue was primarily driven by the increases in license and royalty revenue due to the recognition of deferred revenues from the termination of license and supply agreements, increases in co-development and research fees partially offset by decreases in manufacture and supply revenue. Excluding this one-time recognition of deferred revenue, total revenues decreased by $3.2 million or 9% year-over-year.

    截至2024年9月30日止九個月的總營收由截至2023年9月30日止九個月的3,740萬美元增加至4,570萬美元。營收增加22%主要是因終止授權與供應協議而認列遞延收入,帶動授權與權利金收入增加,以及共同開發與研究費用增加;但部分被製造與供應收入下降所抵銷。若排除這一次性遞延收入認列,總營收年減320萬美元,或年減9%。

  • Research and development expenses increased to $5.3 million in the third quarter 2024 from $3.2 million in the third quarter of 2023. The increase in research and development expenses was primarily due to the clinical trial cost and product research expenses associated with the continued advancement of our Anaphylm development program and an increase in share-based compensation.

    研發費用由2023年第三季的320萬美元增加至2024年第三季的530萬美元。研發費用增加主要是由於持續推進Anaphylm開發計畫所產生的臨床試驗成本與產品研究費用,以及股份基礎給付增加。

  • Research and development expenses increased to $15.4 million for the nine months ended September 30, 2024, from $10.2 million for the nine months ended September 30, 2023. The increase in research and development expenses was primarily due to the clinical trial costs associated with the continued advancement of the Anaphylm and AQST-108 programs as well as an increase in personnel costs and share-based compensation.

    截至2024年9月30日止九個月的研發費用由截至2023年9月30日止九個月的1,020萬美元增加至1,540萬美元。研發費用增加主要是由於持續推進Anaphylm與AQST-108計畫所產生的臨床試驗成本,以及人員成本與股份基礎給付增加。

  • Selling, general and administrative expenses increased to $12.1 million for the third quarter of 2024 from $7.4 million in the third quarter of 2023. This increase was partially driven by a $1.5 million year-over-year change in the allocation of expenses of manufactured and supply cost. Given this year-over-year change, the company expects to continue to see a positive benefit in gross margin, offset by somewhat higher selling, general and administrative expenses. Excluding this item, increases in SG&A expenses were primarily driven by increased commercial spending and regulatory fees related to the approval of Libervant and the commercial preparations for Anaphylm.

    2024年第三季銷售、一般及行政費用由2023年第三季的740萬美元增加至1,210萬美元。此增加部分是由於製造與供應成本費用分攤方式的年對年變動,影響金額為150萬美元。鑑於此年對年變動,公司預期將持續看到毛利率的正面效益,但會被略高的銷售、一般及行政費用所抵銷。若排除此項因素,SG&A費用增加主要來自商業化支出增加,以及與Libervant核准及Anaphylm商業化準備相關的法規費用。

  • Selling, general and administrative expenses increased to $34.2 million for the nine months ended September 30, 2024, from $22.2 million for the nine months ended September 30, 2023. The increase included severance cost of $1.1 million incurred in the first three months of the year, and $4.1 million due to the year-over-year change in the allocation of manufacturer and supply cost. The remainder of the increase is largely driven by higher commercial spending and regulatory fees related to the approval of Libervant, the commercial preparations for Anaphylm partially offset by lower legal fees and decreases in other general and administrative costs, including insurance fees.

    截至2024年9月30日止九個月的銷售、一般及行政費用由截至2023年9月30日止九個月的2,220萬美元增加至3,420萬美元。增加項目包括年初前三個月發生的110萬美元資遣費,以及因製造與供應成本分攤方式年對年變動而增加的410萬美元。其餘增加主要由較高的商業化支出與與Libervant核准、Anaphylm商業化準備相關的法規費用所帶動,但部分被較低的法律費用及其他一般及行政成本(包括保險費用)下降所抵銷。

  • Aquestive's net loss for the third quarter 2024 was $11.5 million or $0.13 for both basic and diluted loss per share compared to the net loss for the third quarter of 2023 of $2 million or $0.03 for both basic and diluted loss per share. The increase in net loss was primarily driven by increases in selling, general and administrative expenses, research and development expenses, noncash interest expense related to the amortization of the debt and royalty obligation discounts and decreases in interest income and other income, partially offset by increases in revenues and decreases in manufacturing and supply expenses.

    Aquestive 於 2024 年第三季的淨損為 1,150 萬美元,或每股基本及稀釋後虧損 0.13 美元;相較之下,2023 年第三季的淨損為 200 萬美元,或每股基本及稀釋後虧損 0.03 美元。淨損增加主要係由於銷售、一般及行政費用增加、研發費用增加、與債務及權利金義務折價攤銷相關的非現金利息費用增加,以及利息收入與其他收入減少所致;部分被營收增加及製造與供應費用下降所抵銷。

  • Aquestive's net loss for the nine months ended September 30, 2024, was $27.1 million or $0.32 for both basic and diluted loss per share compared to the net income for the nine months ended September 30, 2023, of $0.2 million or $0.00 for both basic and diluted loss per share. The increase in net loss was primarily driven by the items previously mentioned.

    截至 2024 年 9 月 30 日止九個月,Aquestive 的淨損為 2,710 萬美元,或每股基本及稀釋後虧損 0.32 美元;相較之下,截至 2023 年 9 月 30 日止九個月的淨利為 20 萬美元,或每股基本及稀釋後 0.00 美元。淨損增加主要由前述項目所驅動。

  • Non-GAAP adjusted EBITDA loss was $6.6 million in the third quarter of 2024 compared to a non-GAAP adjusted EBITDA loss of $1.3 million in the third quarter of 2023. Non-GAAP adjusted EBITDA loss, excluding adjusted R&D expenses, was $1.6 million in the third quarter 2024 compared to a non-GAAP adjusted EBITDA income, excluding R&D expenses, of $1.7 million in the third quarter of 2023. Non-GAAP adjusted EBITDA loss was $11.9 million for the nine months ended September 30, 2024, compared to a non-GAAP adjusted EBITDA loss of $8.5 million for the nine months ended September 30, 2023. Non-GAAP adjusted EBITDA income, excluding adjusted R&D expenses, was $2.6 million for the nine months ended September 30, 2024, compared to a non-GAAP adjusted EBITDA income, excluding R&D expenses, of $1.3 million for the nine months ended September 30, 2023.

    2024 年第三季非 GAAP 調整後 EBITDA 虧損為 660 萬美元,較 2023 年第三季非 GAAP 調整後 EBITDA 虧損 130 萬美元增加。2024 年第三季非 GAAP 調整後 EBITDA 虧損(不含調整後研發費用)為 160 萬美元;相較之下,2023 年第三季非 GAAP 調整後 EBITDA(不含研發費用)為 170 萬美元的獲利。截至 2024 年 9 月 30 日止九個月,非 GAAP 調整後 EBITDA 虧損為 1,190 萬美元;相較之下,截至 2023 年 9 月 30 日止九個月非 GAAP 調整後 EBITDA 虧損為 850 萬美元。截至 2024 年 9 月 30 日止九個月,非 GAAP 調整後 EBITDA(不含調整後研發費用)為 260 萬美元的獲利;相較之下,截至 2023 年 9 月 30 日止九個月非 GAAP 調整後 EBITDA(不含研發費用)為 130 萬美元的獲利。

  • Cash and cash equivalents were $77.9 million as of September 30, 2024. During the third quarter, we did not sell any shares under our ATM facility. We continue our focus in 2024 on the advancement of Anaphylm, epinephrine and AQST-108 programs and continued commercialization of Libervant for patient ages between two and five years old.

    截至 2024 年 9 月 30 日,現金及約當現金為 7,790 萬美元。於第三季期間,我們未透過 ATM(隨市發行)融資機制出售任何股份。我們在 2024 年持續聚焦於推進 Anaphylm、腎上腺素(epinephrine)及 AQST-108 計畫,並持續推動 Libervant 於 2 至 5 歲患者族群的商業化。

  • As outlined in the press release issued last night after market close, our outlook for 2024 remains unchanged at total revenues of approximately $57 million to $60 million and non-GAAP adjusted EBITDA loss of approximately $20 million to $23 million. Our guidance for 2024 includes, for Anaphylm, conclusion of the supportive studies, engaging the FDA in a pre-NDA meeting this quarter, commencing a pediatric study and pre-commercial activities for a planned launch in the first quarter of 2026, if approved by the FDA. Our guidance also includes continued expansion of the commercial launch of Libervant for patients ages between two and five and the advancement of our AQST-108, epinephrine topical gel program.

    如同昨晚收盤後發布的新聞稿所述,我們對 2024 年的展望維持不變:總營收約 5,700 萬至 6,000 萬美元,非 GAAP 調整後 EBITDA 虧損約 2,000 萬至 2,300 萬美元。我們對 2024 年的指引包含:就 Anaphylm 而言,完成支持性研究、本季與 FDA 進行 NDA 前會議(pre-NDA meeting)、啟動兒科研究,以及為計畫於 2026 年第一季上市(若獲 FDA 核准)所進行的上市前商業活動。我們的指引亦包含:持續擴大 Libervant 於 2 至 5 歲患者的商業上市推進,以及推進我們的 AQST-108 腎上腺素外用凝膠計畫。

  • With that, I will now turn the line back to the operator to open the line for questions.

    接下來,我將把電話交回給接線員,開放提問。

  • Operator

    Operator

  • Thank you. (Operator Instructions)

    謝謝。(接線員指示)

  • Roanna Ruiz, Leerink Partners.

    Leerink Partners 的 Roanna Ruiz。

  • Roanna Ruiz - Analyst

    Roanna Ruiz - Analyst

  • Hi, good morning, everyone. Two questions from me. First one for Anaphylm and the clinical briefing book. I was curious what topics you seek to highlight most to the FDA? And if you're able to share what were some of your main goals when assembling the data for this briefing book?

    嗨,各位早安。我有兩個問題。第一個是關於 Anaphylm 與臨床簡報資料(clinical briefing book)。我想了解你們最希望向 FDA 強調哪些主題?以及若方便分享,在彙整這份簡報資料時,你們的主要目標是什麼?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Good morning, Roanna, do you have a second question? Or was that...

    早安,Roanna,你還有第二個問題嗎?還是那個……

  • Roanna Ruiz - Analyst

    Roanna Ruiz - Analyst

  • Second question was on Libervant. So I was also curious how did the initial negotiations go with the first two PBMs? And if you have any color around that?

    第二個問題是關於 Libervant。我也想了解,與前兩家 PBM 的初步談判進展如何?以及你們是否能提供一些補充說明?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. So let me -- I'll talk to the Anaphylm question, and then I'll hand it over to Sherry, who will give you her view of how the negotiations have gone. Though I may not be able to help myself and might give you a comment or two. In terms of the clinical briefing book for Anaphylm, look, as you know, we are exactly where we wanted to be. We -- when we look at the goal of that meeting, it's very simple. We have done everything the FDA has asked us to do to date. We think the results of what we have produced are positive, as we've shared with the public. And we're looking for the FDA to provide us their guidance on the completeness of our package. So we think we're well positioned. We think we put our best foot forward, and we're excited for that upcoming meeting.

    當然。我先回答 Anaphylm 的問題,接著我會把問題交給 Sherry,請她分享她對談判進展的看法。不過我可能也忍不住會補充一兩點。就 Anaphylm 的臨床簡報資料而言,你也知道,我們正處於我們希望達到的位置。我們——當我們看這次會議的目標,其實非常簡單。截至目前,我們已完成 FDA 要求我們做的所有事項。我們認為我們所產出的結果是正面的,正如我們已對外分享。我們希望 FDA 就我們資料包的完整性提供指引。因此我們認為我們處於有利位置。我們認為我們已盡最大努力呈現最佳狀態,並且對即將到來的會議感到期待。

  • In terms of Libervant in the negotiations, I also couldn't be happier with the work that Sherry and her team have done in terms of getting us positioned well. And I'll let her walk you through what she's seeing so far.

    至於 Libervant 的談判,我對 Sherry 與她的團隊所做的工作也再滿意不過,讓我們在定位上非常到位。我讓她帶你了解她目前看到的情況。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Thanks, Dan. Hi, Roanna, how are you? Thanks so much for the question. Our negotiations thus far with our account team have been very, very positive. What we're finding, in both at the state Medicaid level as well as with the commercial PBM, is that as long as the product is being prescribed, for patients ages two to five, we are getting -- Libervant is getting covered for these patients. And so we continue to broaden our reach into the downstream payers as well. And again, it is very consistent. There is a significant unmet need in the market. And for patients ages two to five, it is really being seen by physicians and payers as a game changer.

    謝謝你,Dan。嗨,Roanna,你好嗎?非常感謝你的提問。截至目前,我們的客戶團隊所進行的談判非常、非常正面。我們發現,無論是在州層級的 Medicaid,或是商業 PBM,只要產品有被開立處方、且是針對 2 至 5 歲患者,Libervant 就能獲得這些患者的給付涵蓋。因此我們也持續擴大在下游支付方的觸及。而且再次強調,情況非常一致。市場上存在顯著的未被滿足需求。對於 2 至 5 歲患者而言,醫師與支付方確實將其視為改變遊戲規則的產品。

  • Roanna Ruiz - Analyst

    Roanna Ruiz - Analyst

  • Got it. That's great. And one quick follow-up for Libervant. I noticed you mentioned you have Medicaid coverage now. When should we expect that to start to impact prescribing going forward?

    了解。很好。另外一個關於 Libervant 的簡短追問。我注意到你提到現在已取得 Medicaid 給付。我們應該何時預期這會開始對未來的處方量產生影響?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Well, I would remember to think about the two to five-year-old spaces we've guided before. From a financial perspective or a size perspective, that will be limited in scope and what that does for Aquestive in 2025, where I would have people look in terms of results and what we're driving for the company, is our ability to get coverage, drive patients to our product, which we believe is a better product than the product that's in the two to five-year-old space right now, and get our scripts to grow accordingly. So I believe we're on track to do that with now our national sales force in place for -- Sherry, what -- all of three weeks at this point, three or four weeks?

    嗯,我會提醒大家回想我們先前對 2 至 5 歲市場空間所提供的指引。從財務角度或市場規模角度來看,那部分的影響範圍會相對有限;至於它在 2025 年能為 Aquestive 帶來什麼,我希望大家關注的是:我們取得給付涵蓋的能力、將患者導向我們的產品(我們相信這比目前 2 至 5 歲市場上的產品更好),並讓我們的處方量隨之成長。因此我相信我們正按計畫推進;我們的全國性銷售團隊已到位——Sherry,現在大概才……三週?三或四週?

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Four weeks, yes.

    四週,是的。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • And we're really excited by the feedback we're getting so far. So while it will be financially small until we are able to access the entire market in the years to come, we think the learnings we're getting are the places to focus on as we go forward.

    而且我們對目前收到的回饋感到非常振奮。因此,雖然在未來幾年我們能夠觸及整個市場之前,財務貢獻會相對有限,但我們認為目前獲得的學習與洞見,將是我們接下來推進時應聚焦的重點。

  • Roanna Ruiz - Analyst

    Roanna Ruiz - Analyst

  • That's great. Thanks.

    太好了。謝謝。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • David Amsellem, Piper Sandler.

    David Amsellem,Piper Sandler。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • Thanks. So I just have a couple. First, regarding the NDA for Anaphylm, are you going to assume or at least prepare for an Ad Comm, particularly given the experience with neffy, how are you thinking about that or how should we think about that? That's number one.

    謝謝。我這邊有幾個問題。第一,關於 Anaphylm 的 NDA,你們是否會假設或至少為召開 Ad Comm(諮詢委員會)做準備?特別是考量到 neffy 的經驗,你們是怎麼思考的,或我們應該怎麼看待這件事?這是第一個。

  • Number two, can you just remind us how you're thinking about the initial sales force for Anaphylm? I'm specifically interested in, how are you thinking about prescriber concentration along EpiPen and what that means in terms of your target audience and initial sales force headcount?

    第二,能否提醒我們你們對 Anaphylm 初期銷售團隊的規劃?我特別想了解的是:你們如何看待 EpiPen 相關的處方醫師集中度,以及這對你們的目標受眾與初期銷售人力編制(headcount)意味著什麼?

  • And then lastly, Libervant question, which is as you have executed on regarding payers and obviously launching into that two to five segment, is it more likely or just as likely that you're going to continue to keep rights to the product and ultimately, over the long term, launch it in a wider population? In other words, is this asset core to the overall mission of Aquestive? Thank you.

    最後一個是關於 Libervant:隨著你們在付款方(payers)方面的執行,並且顯然是先在 2 到 5 歲族群推出,未來你們更可能、或同樣可能會繼續保留該產品權利,並最終在長期內把它推向更廣泛的人群嗎?換句話說,這個資產是否是 Aquestive 整體使命的核心?謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. Good morning, David. So I think I captured the three questions. And let me -- just for fun this morning. Let me go in reverse order. So I'll answer your question on Libervant. I'll then hand it to Sherry, who could talk about the concentration of prescribers for Anaphylm. And then Carl, you can close it out for us on your view on Ad Comm. But so your question on Libervant, I think, is a great one because it goes back to what are we trying to accomplish as a company. And if you look at what we've done over the last couple of years, this is a steady march to building a continuously more valuable company. So we've got three different products that we think are all very valuable, Anaphylm, 108 and Libervant, and we'll continue to pursue maximizing the value of those products for all our stakeholders, obviously, the patient but also the shareholders.

    當然。早安,David。我想我已經抓到這三個問題了。那我——今天早上就稍微有趣一點。我先倒著回答。我會先回答你關於 Libervant 的問題。接著我會交給 Sherry,她可以談談 Anaphylm 的處方醫師集中度。然後 Carl,你再幫我們收尾,談談你對 Ad Comm 的看法。至於你對 Libervant 的問題,我認為問得很好,因為這回到我們公司想要達成什麼。如果你看我們過去幾年的作為,這是一個穩健的進程,目標是打造一家持續更有價值的公司。我們有三個不同的產品,我們認為都非常有價值:Anaphylm、108 和 Libervant;我們會持續追求為所有利害關係人最大化這些產品的價值,當然包括病患,也包括股東。

  • So with Libervant in particular, right now, we think we're incredibly well placed. We're able to launch our product into a very specific area, get all of the infrastructure pieces and parts up and running, get learnings for Anaphylm, and that's all very beneficial to us. So right now, our focus with Libervant is on growing it in the two to five-year-old space. When the opportunity comes to be in the six and up space, we absolutely want to be front and center and ready to launch. In terms of all of our products, whether we hold on to all of the efforts ourselves or augment our efforts with other people's sales forces, that is purely whether it falls into our ability to grow the company or not. So we will always look to what's the best for the company and what's the best for the shareholders on all of our assets. But with that, let me pass it over to Sherry on the Anaphylm questions specifically.

    就 Libervant 而言,目前我們認為我們的定位非常好。我們能把產品先在一個非常特定的領域上市,把所有基礎建設的各個環節建置並運轉起來,同時為 Anaphylm 取得學習與經驗,這些對我們都非常有利。因此目前我們對 Libervant 的重點,是在 2 到 5 歲的市場空間推動成長。當進入 6 歲以上族群的機會到來時,我們絕對希望站在最前線並做好上市準備。就我們所有產品而言,無論是由我們自行保留並投入所有商業化工作,或是透過其他公司的銷售團隊來補強,完全取決於這是否符合我們擴大公司成長能力。因此,我們會一貫地就所有資產評估:什麼對公司最好、什麼對股東最好。那麼接下來我把問題交給 Sherry,請她針對 Anaphylm 的問題做更具體的說明。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Hi, David, thank you so much for the question. It's a really exciting time here at Aquestive as it relates to our commercial readiness. We are -- we have our plans in place to ensure we have a very successful launch. As it relates specifically to the sales force, this is a well-worn path as the allergist continues to be the most productive specialty -- they prescribe approximately 200 epinephrine prescriptions annually. So our focus for our sales force will be on those allergists and then the high decile prescribing PCPs, otolaryngologists, NPPA and pediatricians. And we believe, based on the expertise that we have here in house, as that sales force about the size of 100 reps, we will be able to cover those large prescribing physicians. Does that answer your question?

    嗨,David,非常感謝你的提問。就我們的商業化就緒度而言,這對 Aquestive 來說是非常令人振奮的時刻。我們——我們已經制定好計畫,以確保能非常成功地上市。就銷售團隊而言,這是一條已被反覆驗證的路徑,因為過敏專科醫師仍然是最具產能的專科——他們每年大約開立 200 張腎上腺素處方。因此,我們銷售團隊的重點會放在這些過敏專科醫師,接著是處方量位於高十分位(high decile)的基層照護醫師(PCP)、耳鼻喉科醫師、NPPA 以及小兒科醫師。我們相信,基於我們內部具備的專業能力,約 100 名業務代表規模的銷售團隊,就能覆蓋這些高處方量的醫師。這樣有回答到你的問題嗎?

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • Yeah, that's helpful. Thank you.

    有的,這很有幫助。謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thank you. And Carl, can you give your view on the Ad Comm.

    謝謝。那 Carl,你能談談你對 Ad Comm 的看法嗎?

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Sure. Happy to. Good morning. So obviously, I can't predict what the FDA will do. I can say that we have risk mitigated this program tremendously. All of our primary and secondary endpoints have been met for all of our studies, whether it's our pivotal or self-administration or temperature/pH and most recently, the Oral Anaphylm Symptom Intervention Study, the OASIS study. We're certainly considering the possibility, and we'll be prepared for this to become an avenue that FDA pursues. But right now, we don't have insight into the FDA's thinking.

    當然。很樂意。早安。很明顯,我無法預測 FDA 會怎麼做。但我可以說,我們已大幅降低這個專案的風險。我們所有研究的主要與次要終點都已達成,不論是關鍵性試驗(pivotal)、自行給藥(self-administration)、溫度/pH,或是最近的口服 Anaphylm 症狀介入研究——OASIS 研究。我們當然有在考量這種可能性,也會做好準備,以防這成為 FDA 會採取的一條途徑。但目前我們並沒有掌握 FDA 的想法。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • Okay. Appreciate all the color. Thanks everyone.

    好的。很感謝你們提供這麼多細節。謝謝各位。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • Francois Brisebois, Oppenheimer.

    Francois Brisebois,Oppenheimer。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Hey, thanks for the question. So I was just wondering, you touched on the allergen test and the study. And I was just trying to figure out the importance of efficacy here based on this study, just in terms of real-world adoption with doctors. And just maybe a little more if you could push on the potential importance here of treating at the site to see benefit. Is this something that can help in the real world just because like a lot of launches, docs will kind of wait and see sometimes how things work?

    嗨,謝謝讓我提問。我想請教一下,你們提到了過敏原測試與該研究。我想釐清的是,基於這項研究,在醫師的真實世界採用(adoption)上,療效的重要性有多大?另外,如果可以的話,也想再深入一點談談在反應部位進行治療、以看到效益的潛在重要性。這是否能在真實世界中帶來幫助?因為像很多產品上市一樣,醫師有時候會先觀望,看看實際效果如何。

  • And I was just wondering if the OAS study is something that should really create some buzz with the medical community? Thank you.

    我也想請問,OAS 研究是否應該能在醫學界引起一些討論熱度(buzz)?謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. Good morning, Frank. And I'll pass it over to Carl in a second to walk through your full question. But I have to tell you, from my perspective, we're incredibly excited to have this data. We think this is a differentiator. As far as we're aware, we're the only ones with data like this, and we absolutely from the recent interactions at several conferences with physicians think they're paying attention. But with that, I'll let Carl answer your specific questions.

    是的。早安,Frank。我等一下會把問題交給 Carl,請他完整說明你的問題。但我必須說,就我個人觀點,我們對這些數據感到非常興奮。我們認為這是一個差異化優勢。就我們所知,我們是唯一擁有這類數據的公司;而且從最近在幾個會議上與醫師的互動來看,我們確實認為他們正在關注。不過接下來我讓 Carl 回答你更具體的問題。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yeah. No, that's a good question. And I can tell you, both anecdotally and meeting with a number of KOLs, there was widespread support that these data do indicate delivery of epinephrine into the oral cavity probably does hold promise when you think about interrupting the anaphylactic cycle or certainly localized reactions in the oral cavity. I hadn't realized this, but many allergists actually use the direct spraying of epinephrine into the back of the oral cavity when these symptoms do arise as a way of trying to get more drug at the site of reaction.

    是的。不,這是個好問題。我可以告訴你,無論是從一些軼事經驗,或是與多位關鍵意見領袖(KOL)會面後的觀察,都有廣泛的支持認為:這些數據確實顯示,將腎上腺素送達口腔內,當你思考中斷過敏性休克循環,或至少是口腔內的局部反應時,可能具有潛力。我之前並不知道,但許多過敏專科醫師在這些症狀出現時,實際上會直接把腎上腺素噴到口腔後部,作為一種嘗試在反應部位提供更多藥物的方法。

  • Also worth noting that we do have, for the first time, an oral physiologic change model that hadn't been developed before, and those changes did not impact Anaphylm absorption, as Dan said earlier, we certainly shrink time to symptom resolution. All of those in my mind certainly underscore the fact that we now have a potentially predictive model that one could use and think about when it comes to evaluating anaphylaxis. So useful for many different regards.

    另外也值得注意的是,我們確實首次擁有一個先前未曾建立的口腔生理變化模型,而如 Dan 先前所說,這些變化並未影響 Anaphylm 的吸收;我們也確實縮短了症狀緩解所需的時間。在我看來,這些都清楚凸顯了:我們現在有一個可能具備預測性的模型,可在評估過敏性休克時加以運用並納入考量。因此在許多不同面向都很有用。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Thank you. And then just -- go ahead.

    謝謝。然後就是——請繼續。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • I was just going to say, we just released these results I don't know, less than 10 -- or maybe about 10 days ago, and we didn't have the opportunity to hold a conference at that time with this community. So we really appreciate you bringing this up because this is a big major point for our program. But anyway, you were going to ask an additional question I think?

    我只是想說,我們大概在不到 10——或大約 10 天前才剛發布這些結果,而當時沒有機會與這個社群召開會議。所以我們非常感謝你提出這點,因為這是我們計畫中一個非常重大的重點。不過總之,我想你還要再問一個問題?

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Great. No, I think it makes a lot of sense. I just wanted to -- this is not as much a question as I just -- I don't think I heard it quite right. The percentage you mentioned, I think, 10% progressed with the allergen test. I just -- you mentioned a percentage in terms of patients that progressed to anaphylaxis in the real world. Can you just repeat what that was in your prepared remarks?

    很好。不,我覺得這很有道理。我只是想——這與其說是問題,不如說我——我覺得我可能沒有聽得很清楚。你提到的比例,我想是 10% 在過敏原測試後有進展。我只是——你也提到在真實世界中,病人進展到過敏性休克的比例。你可以把你在事先準備的發言中提到的那個數字再重複一次嗎?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. My prepared remarks and Carl can add to it if you would like to take deeper, was that in oral allergy syndrome, so OAS, which was the model we used for the study, there are a percentage of patients when they have an OAS reaction do progress into anaphylaxis. So the literature says that around 10% -- it's 9% to 10%, have a more severe allergic reaction that progresses from their initial reaction and 2% actually end up with anaphylaxis. So we're simply making the point that OAS is somewhere on the continuum of anaphylaxis.

    當然。我在準備好的發言中提到——如果你願意更深入,Carl 也可以補充——在口腔過敏症候群(oral allergy syndrome,OAS)中,也就是我們在研究中使用的模型,有一部分病人在發生 OAS 反應時確實會進展為過敏性休克。文獻指出大約有 10%——約 9% 到 10%——會出現更嚴重的過敏反應,從初始反應進一步惡化,而其中有 2% 最終會發展為過敏性休克。所以我們只是要強調,OAS 位於過敏性休克連續譜上的某個位置。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Okay. It's 2% of the total? Not 2% of that 10% sort of?

    好的。是總體的 2%?不是那 10% 裡面的 2% 之類的?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • It's 2% of the total. That's correct.

    是總體的 2%。沒錯。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Okay. Perfect. Thank you.

    好的。非常好。謝謝。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • Raghuram Selvaraju, HC Wainwright & Co.

    Raghuram Selvaraju,HC Wainwright & Co.。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • Thanks so much for taking my question and congrats on all the progress. Can you hear me?

    非常感謝讓我提問,也恭喜你們取得所有進展。你們聽得到我嗎?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • We can hear you just fine, Ram.

    我們聽得很清楚,Ram。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • Okay. Very quickly. With respect to Libervant, I was wondering if you could comment on two things. One is the overall pricing paradigm that currently prevails with respect to VALTOCO and what you believe is likely to be the implication for the future introduction of Libervant into the adult population? Any kind of thoughts there? Any granularity you can provide to us regarding where the pricing levels are?

    好的。很快問一下。關於 Libervant,我想請你們評論兩件事。第一是目前就 VALTOCO 而言,整體的定價模式(pricing paradigm)是什麼?你們認為這對未來將 Libervant 導入成人族群可能會有什麼影響?對此有任何想法嗎?你們能否提供一些更細的資訊,讓我們了解目前的定價水準大概落在哪裡?

  • And secondly, you mentioned in the press release that you will be filing for approval of Libervant in that population ahead of the expiration of orphan drug exclusivity on VALTOCO. But I wanted to better understand what that means? How far in advance of the expiration of exclusivity in early 2027, do you expect to file? And what are the likely implications of that with respect to the FDA path forward? Thanks.

    第二,你們在新聞稿中提到,會在 VALTOCO 的孤兒藥獨占期到期之前,針對該族群提交 Libervant 的核准申請。但我想更清楚了解這代表什麼?在 2027 年初獨占期到期之前,你們預計會提前多久送件?而這對 FDA 後續審查路徑可能會有什麼影響?謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. And thanks, Ram. Let me start with the Libervant filing question because that's largely just a technical question. So the way it works is we have to submit our administrative filing, I'll call it, six months before we're requesting the date of approval, right? So we would just time that based on when the ODE exclusivity expires. And we also still have to complete the approval process for the 6 to 11 because we were obviously focused in other places. So that -- most of that will be behind the scenes because it's just technical FDA paperwork, I'll call it. But rest assured, our plan and the work we'll be doing will set us up and our goal continues to be that the day we're allowed to sell in the six and up population. So six and up in all adult that we will not only be ready, but we will be approved and in the market.

    好的。謝謝你,Ram。我先從 Libervant 送件的問題開始,因為那主要是技術性問題。運作方式是:我們必須在我們希望核准的日期之前六個月,提交我稱之為行政性送件(administrative filing)的資料,對吧?所以我們會依據 ODE 獨占期到期的時間來安排。而且我們也仍需完成 6 到 11 歲族群的核准流程,因為我們先前顯然把重點放在其他地方。因此——其中大部分會在幕後進行,因為我會把它稱為技術性的 FDA 文書作業。但請放心,我們的計畫以及將進行的工作,會讓我們做好準備;我們的目標仍然是:在我們被允許於 6 歲以上族群銷售的那一天——也就是 6 歲以上、包含所有成人——我們不僅會準備就緒,也會取得核准並進入市場。

  • On the pricing side, I would give you this to think about what we're finding so far with launch is this is a rescue product. This is a rescue product in epilepsy and right now in pediatrics. So we have not found price to be an obstacle. We have not found coverage to be an obstacle. We have not found in places where there's still a prior auth because we're going through the contracting process. We have not found prior auths to be a problem. So we feel that the payer community understands the necessity of the product and is acting accordingly. In terms of how pricing dynamics will come when we have access to the full market, we have no reason to believe right now that they would be materially different than they are today.

    在定價方面,我想提供你一個思考方向:就目前上市推進的觀察,這是一個救援用產品。這是癲癇領域的救援用產品,而且目前是在兒科。因此我們尚未發現價格是障礙。我們尚未發現給付(coverage)是障礙。我們也尚未發現,在仍需要事前授權(prior auth)的地方——因為我們正在進行合約談判流程——事前授權會成為問題。所以我們認為支付方社群理解此產品的必要性,並且正採取相應作法。至於當我們能觸及完整市場時,定價動態會如何發展,我們目前沒有理由相信會與今天有實質差異。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • Okay. That's very helpful. Somewhat analogous question with respect to Anaphylm. Since neffy is on the market, I was wondering if you intend to do any kind of prescriber outreach or market research to kind of assess who the high-value prescribers or high frequency prescribers of neffy are? Who might not necessarily be completely on board with prescribing neffy? And in those kind of two general populations of prescribers, what sort of product characteristics that are embodied by Anaphylm product profile as seen so far would be most likely to appeal to them -- sort of as a precursor to engaging in sort of full-blown launch preparations for the product?

    好的。這很有幫助。再問一個與 Anaphylm 相關、某種程度類似的問題。既然 neffy 已經上市,我想知道你們是否打算做任何處方醫師外展(prescriber outreach)或市場研究,以評估哪些是 neffy 的高價值處方者或高頻處方者?以及哪些人可能未必完全願意開立 neffy?而在這兩大類處方者中,依目前看到的 Anaphylm 產品特性(product profile),哪些特點最可能吸引他們——作為你們在全面啟動產品上市準備之前的一個前置工作?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. Well, in a second, I'll hand it over to Sherry, who could just walk you through the survey type work in general that we're undertaking and preparing. But what I would say, as a general comment, is one of the nice things about watching a competitor launch in this space, is exactly that. We're getting to watch. So we absolutely are watching the pricing dynamics, watching the prescriber habits and reaction, watching the spots where things work, watching the spots where things don't work. So we continue to believe that this is not a zero-sum game for the space that the product -- the patient need is high. And that as patients learn about alternate products, they will be looking for what fits them best, which I think leads to your question of what characteristics in our survey work that we think are most exciting for us, which I'll let Sherry cover for you.

    是的。我等一下會把問題交給 Sherry,請她帶你了解我們一般正在進行與準備的調查類工作。但我想先做一個總體評論:在這個領域觀察競品的上市,其中一個好處正是如此。我們可以觀察。所以我們確實在觀察定價動態、觀察處方習慣與反應、觀察哪些地方運作順利、哪些地方不順利。因此我們仍然相信,這個領域不是零和賽局;產品——病人的需求很高。而且當病人了解替代產品時,他們會尋找最適合自己的選項;我想這也引出你關於我們在調查工作中認為哪些特性最令我們振奮的問題,這部分我就讓 Sherry 為你說明。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Sure. Hi, Ram, thanks so much for these questions. It's rare to be able to launch multiple products that are game changers. But I can tell you, again, based on market research, we were engaged in over the last few weeks, it is a common term that physicians are using game changers for their patients. And why is that? Well, if you think about it, this product category has a significant unmet need. And when you -- as you know, about anaphylaxis, it is a condition that can -- comes on rapidly and can lead to very challenging outcomes. So it is critical for patients to have an epinephrine product so they can easily use and easily carry.

    當然。嗨,Ram,非常感謝你提出這些問題。能夠推出多款具有顛覆性的產品是很罕見的。但我可以再告訴你,根據我們在過去幾週進行的市場調查,「顛覆性」是醫師常用來形容其病患的用語。那是為什麼呢?嗯,如果你想一想,這個產品類別存在顯著未被滿足的需求。而且如你所知,關於過敏性休克(anaphylaxis),這是一種可能會——發作迅速,並可能導致非常棘手結果的病況。因此,病患能擁有一款腎上腺素產品,能夠容易使用、也容易攜帶,是至關重要的。

  • And so again, all of our market research comes back to saying, Anaphylm is the easiest to carry. It is the easiest to use. And on top of that, you have the great efficacy. It's working quickly and consistently. So at the end of the day, who are the patients? Well, we think -- look, we're watching, obviously, very closely, and we'll continue to watch, as Dan has shared. But you're always going to have those physicians that are quick adopters. You're going to have patients that are quick adopters. And so we also believe that patients with an active prescription, neffy or their devices, will be quick adopters of our products, both patients and HCPs. We believe that patients that are newly diagnosed, that don't yet have a prescription, but neffy will -- or excuse me, Anaphylm will be the preferred option. And finally, we see this market expanding in that patients that have never filled a prescription and just avoid their allergen will be a great patient too for the product.

    所以再說一次,我們所有的市場調查都回饋指出,Anaphylm 最容易攜帶。它也最容易使用。除此之外,它還具備很好的療效。起效快速且一致。所以歸根結底,病患是哪些人?嗯,我們認為——你看,我們當然會非常密切地觀察,並且會持續觀察,正如 Dan 所分享的。但你永遠都會有那些採用速度快的醫師。也會有採用速度快的病患。因此我們也相信,已有有效處方的病患、neffy 或其裝置的使用者,將會是我們產品的快速採用者——包括病患與醫療照護專業人員(HCPs)。我們相信,新近被診斷、尚未有處方的病患,neffy 將——或更正,Anaphylm 將會是偏好的選項。最後,我們看到這個市場正在擴大:那些從未領取處方、只是避免其過敏原的病患,也會是這款產品很好的目標病患。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • Great. Thanks. And very quickly, one last thing with respect to 108. Given the timeline that you've laid out with respect to the IND and initiation of the Phase 2a trial, are we to assume that this effectively falls within the scope of the previous timeline guidance that you provided indicating an expectation that this product could be launched before the end of 2028? Just wanted to make sure that things are still effectively on track relative to what you previously showcased at the Investor Day event?

    很好。謝謝。另外很快地,關於 108 還有最後一點。依照你所說明的 IND 時程與第 2a 期試驗啟動時點,我們是否可以假設,這基本上仍落在你先前提供的時程指引範圍內——也就是預期該產品可在 2028 年底前上市?只是想確認,相較於你們先前在投資人日活動所展示的內容,事情是否仍然基本上按計畫推進?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes, Ram. We're very excited and very serious about 108. We've already, as you heard from the comments before in our press release, we've already put our briefing book into the FDA. We are ready to file our IND and we want to get our Phase 2a going. So absolutely on schedule, just like we laid out just a few weeks ago.

    是的,Ram。我們對 108 非常興奮,也非常認真看待。我們已經——如你先前從新聞稿的評論中聽到的——已經把我們的簡報資料(briefing book)提交給 FDA。我們已準備好提交 IND,也希望啟動我們的第 2a 期。所以絕對按進度進行,就像我們在幾週前所規劃的那樣。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • Thank you very much.

    非常感謝。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • Jason Butler, JMP Securities.

    Jason Butler,JMP Securities。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Hi, thanks for taking the question. Just thinking about the meeting with FDA for Anaphylm, can you maybe talk about -- and obviously, I understand you can't go into a ton of detail here, but what aspects of the product label do you think are still up for debate or discussion? What data do you think that you can discuss with FDA, including the oral allergy challenge study, pediatric study, et cetera, but just anything that can help provide a differentiated picture relative to neffy? Thank you.

    嗨,謝謝讓我提問。我在想關於與 FDA 就 Anaphylm 的會議,你能否談談——當然我理解你不能在這裡透露太多細節——你認為產品標籤(label)的哪些部分仍可能需要辯論或討論?你認為有哪些資料可以與 FDA 討論,包括口服過敏原挑戰研究、兒科研究等等;任何能協助呈現相較於 neffy 的差異化圖像的資訊都可以。謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. Good morning, Jason. I'll hand it over to Carl in a second here. But yes, just in terms of global strategy with a label like any company in our position, while there will be elements of the label that are just standard, we do believe that we have differentiation in a couple of places like you mentioned, the OASIS study, that could be very interesting. But Carl, I'll let you go a little deeper.

    好的。早安,Jason。我等一下把問題交給 Carl。不過是的,就整體標籤策略而言,像我們這樣處境的任何公司一樣,標籤中會有一些元素是標準內容;但我們確實相信在幾個地方具有差異化,例如你提到的 OASIS 研究,可能會非常有意思。但 Carl,我讓你再深入說明一些。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yeah. No. Jason, thank you for the question. And I completely agree. I think there are elements here that are clearly differentiating. We've created and demonstrated utility with regards to thinking about symptom resolution in a relatively predictive model, right? We're actually introducing allergen into the oral cavity where you typically see allergens introduced in people with food allergies. But with regard to the forthcoming pre-NDA meeting, as Dan said earlier, the overarching intent is to align on the completion of the adult program and march forward with the execution of the pediatric program study. So that is really the intent overall, but we're certainly considering all potential opportunities to include the most recent data as a differentiating element.

    是的。沒錯。Jason,謝謝你的問題。我完全同意。我認為這裡有一些元素確實能形成明顯差異化。我們已建立並證明其效用,特別是在相對可預測的模型中思考症狀緩解(symptom resolution),對吧?我們實際上是把過敏原引入口腔——而這正是食物過敏者通常接觸過敏原的途徑。但就即將到來的 pre-NDA 會議而言,如 Dan 先前所說,整體目的在於就成人計畫的完成達成一致,並推進兒科計畫研究的執行。所以整體意圖就是如此,但我們當然也在考量所有可能的機會,把最新資料作為差異化要素納入。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Great. And then just a follow-up for Ernie. I understand you're not going to give guidance for 2025 at this point. But how should we think about the trends for legacy revenues as we exit this year? And I'm not thinking about Libervant or Anaphylm, everything -- but everything that's driven the other revenue streams up until now? What is the tail kind of life of those royalty streams or revenue streams? Thanks.

    很好。接著有個追問給 Ernie。我理解你目前不會提供 2025 年的指引。但我們應該如何看待今年結束時,既有(legacy)營收的趨勢?我不是在問 Libervant 或 Anaphylm,而是——截至目前推動其他營收來源的所有項目。那些權利金收入或營收來源的尾端壽命大概會是怎樣?謝謝。

  • Ernest Toth - Chief Financial Officer, Senior Vice President

    Ernest Toth - Chief Financial Officer, Senior Vice President

  • Well, I think you're asking mostly about Suboxone. Look, we -- as we've said in the past, it is a legacy product for us that continues to generate cash flow. It's an important part of the company. But recognizing that its future and we -- is somewhat questionable at times, depending on the competitive nature of the market, we depend on Indivior for the orders. And we would expect there's going to be some level of dislocation in that market, and that will flow through to us going forward. But we continue to stress, it is an important part of the company. It generates positive cash flow for us. And I think when we provide our guidance for 2025, we will take that into account.

    嗯,我想你主要是在問 Suboxone。你看,我們——如同過去所說,這對我們而言是一項既有產品,仍持續帶來現金流。它是公司重要的一部分。但也要認知到,它的未來——而我們——有時會有些不確定,取決於市場競爭態勢;我們仰賴 Indivior 的訂單。我們預期該市場會出現某種程度的波動/錯位(dislocation),而這將在未來反映到我們身上。但我們仍持續強調,它是公司重要的一部分。它為我們帶來正向現金流。我想當我們提供 2025 年指引時,會把這點納入考量。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Okay, great. Thanks for taking the questions.

    好的,很好。謝謝回答問題。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • Thomas Flaten, Lake Street Capital Markets.

    Thomas Flaten,Lake Street Capital Markets。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Excellent. Good morning and thanks for taking the questions. Sticking with Ernie, for the cash runway into 2026, what level of commercial investment does that contemplate for Anaphylm? Will you have a fully staffed sales force stood up by then within that guidance? Or will you -- does that contemplate something more maybe measured from a sales force perspective?

    很好。早安,謝謝讓我提問。延續 Ernie 的部分,關於現金可支撐到 2026 年的跑道(cash runway),其中對 Anaphylm 的商業化投資水準是如何假設的?在該指引下,屆時你們會建立一支完整編制的銷售團隊嗎?還是——從銷售團隊的角度來看,該假設會更為審慎、循序漸進一些?

  • Ernest Toth - Chief Financial Officer, Senior Vice President

    Ernest Toth - Chief Financial Officer, Senior Vice President

  • So what we have said in the past, Thomas, is the cash gets us into '26. We've not given any more granularity on that. But what we could say is -- here in '24 and '25, that cash supports the launch of -- the expanded launch of Libervant, and that will continue into '25. It includes all pre-commercial activity in '24 and '25 for Anaphylm. But we've also publicly said that we would not be ramping up any sales rep force until we have approval.

    Thomas,我們過去所說的是,現金可支撐我們到 2026 年。我們沒有再提供更細的拆解。但我們可以說的是——在 2024 與 2025 年,這些現金支持 Libervant 的上市——以及擴大上市,而這會延續到 2025 年。其中也包含 2024 與 2025 年 Anaphylm 的所有商業化前(pre-commercial)活動。但我們也已公開表示,在獲得核准之前,我們不會開始擴編任何銷售代表團隊。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Got it. Appreciate that. And is there anything ongoing with respect to trying to overturn the orphan drug exclusivity for Libervant? I know a while back, the major contribution to patient care argument that was trying to be made. Is there anything going on there still?

    了解。感謝。另外,關於試圖推翻 Libervant 的孤兒藥獨占期,是否仍有任何持續進行的事項?我知道前一陣子曾嘗試主張其對病患照護有重大貢獻。那邊現在還有在進行什麼嗎?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah, Thomas. We do have, what I guess I would call, back and forth with the FDA. But as you can see from the way we've positioned the company, that is not where we are putting a lot of our energy right now. So our focus is on the next milestone, and next few milestones for Anaphylm. Our focus is on building Libervant 2 to 5, focuses on getting 108 for alopecia areata through the next couple of milestones. And yes, somewhere behind all of that, there is effort with the FDA. But the main place I would focus in terms of that exclusivity is just watching the clock run out.

    是的,Thomas。我們確實有一些我姑且稱之為與 FDA 之間的來回溝通。但如你從我們對公司的定位所見,這並不是我們目前投入大量精力的地方。因此我們的重點在下一個里程碑,以及 Anaphylm 接下來幾個里程碑。我們的重點在打造 Libervant 2 到 5 歲適應症,重點也在推動 108 用於 斑禿(alopecia areata)通過接下來幾個里程碑。而且是的,在這一切背後,確實也有與 FDA 的相關努力。但就那個獨占期而言,我主要會關注的其實就是看時間自然到期。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Good. Appreciate it. Thank you.

    很好。感謝。謝謝。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • Gary Nachman, Raymond James.

    Raymond James 的 Gary Nachman。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Thanks, good morning. So back on Anaphylm, do you still need to get alignment at all specifically on the pediatric study at the FDA meeting or do you feel you have good visibility on the dosing design for that pediatric study that you're going to start soon after the meeting? And then how will you be prepping the NDA while the PED study is ongoing so that you meet the 1Q '25 filing? And in the CMC feedback, anything you still need to do with manufacturing before the filing? Or is that completely buttoned up?

    謝謝,早安。回到 Anaphylm,你們在 FDA 會議上是否仍需要就兒科研究特別取得一致意見?還是你們覺得對於即將在會後不久啟動的兒科研究,其劑量設計已經有很高的可見度?另外,在 PED 研究進行期間,你們會如何同步準備 NDA,以便達成 2025 年第一季(1Q '25)送件?以及在 CMC 的回饋方面,送件前製造端還需要做什麼嗎?還是已經完全都處理妥當了?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. Good morning, Gary, I'm glad you brought up the CMC because sometimes from our perspective, because we have such a deep history in CMC, we don't talk about it as much as we should. But that was, in my view, a major win for our organization. And I'll pass it over to Steve who can give you his view on what it means for a major part of the NDA, which, by the way, as you know, I think more than half of CRLs that occur are due to the CMC sections of NDAs.

    是的。早安,Gary,我很高興你提到 CMC,因為有時從我們的角度來看,由於我們在 CMC 方面有很深的歷史與經驗,我們反而沒有像應該的那樣多談。但在我看來,這對我們組織而言是一個重大勝利。我把問題交給 Steve,他可以談談這對 NDA 的一個主要部分意味著什麼;順帶一提,如你所知,我認為發生的 CRL 中有一半以上是因為 NDA 的 CMC 章節。

  • Stephen Wargacki - Chief Science Officer

    Stephen Wargacki - Chief Science Officer

  • And thank you, Dan. Gary, yeah, we're really excited about the feedback we got. We were able to align on all of the important features that you just want to present in the best possible way. Having completed all of the work we've needed to do for our filing. But the presentation of that data, the specifications, all of the stability data and things that we're going to use within our NDA and just aligning on exactly how that's presented is a big win to have the cleanest possible filing.

    謝謝你,Dan。Gary,是的,我們對收到的回饋非常振奮。我們得以在所有重要特徵上取得一致,而這些都是你希望以最佳方式呈現的內容。我們也已完成送件所需的所有工作。不過,如何呈現這些資料、規格(specifications)、所有穩定性資料,以及我們將在 NDA 中使用的各項內容,並就其呈現方式精準對齊,這是一個重大勝利,能讓我們的送件盡可能乾淨俐落。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • And going on to the prepping of the NDA, yeah, that -- Gary, as you know, an NDA is a major paperwork undertaking, I'll call it, to get into the FDA. So there are major sections of that NDA that are -- we now have all the information, right? So CMC being one of them. So yes, the work is going on as we speak to prepare the NDA and the information that we gained from whatever is left to do from here forward would be slotted into the document as we get close to filing. In terms of pediatric alignment, I'll let -- while I think you can look at our -- the competitive landscape and see that the pediatric study is fairly standard across all of the different programs. I'll let Gary -- excuse me, I'll let Carl give you, his view.

    至於 NDA 的準備,是的——Gary,如你所知,NDA 是一項龐大的文件工程,我姑且這麼說,要提交給 FDA。因此 NDA 有一些主要章節——我們現在已經具備所有資訊了,對吧?CMC 就是其中之一。所以是的,我們此刻正在進行 NDA 的準備工作;而從現在到送件前仍需完成的任何剩餘事項所取得的資訊,會在接近送件時被納入文件中。至於兒科對齊,我想你可以看看我們的——競爭格局,會發現兒科研究在各個不同計畫中都相當標準化。我讓 Gary——抱歉,我讓 Carl 來分享他的看法。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yeah. Thanks, Dan. Thanks, Gary. The study design itself is quite straightforward, as Dan alluded to. We do and I certainly do expect and anticipate alignment with the FDA for our targeted adolescent study, which would be 7 to 17 using the same dose. So I don't anticipate anything other than moving forward after this pre-NDA meeting.

    是的。謝謝,Dan。謝謝,Gary。研究設計本身相當直接,如 Dan 所提到的。我們確實——而我也確實——預期並期待能在我們鎖定的青少年研究上與 FDA 取得一致,年齡會是 7 到 17 歲,使用相同劑量。因此我不預期會有任何阻礙,這場 pre-NDA 會議之後就會往前推進。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Okay. Great. And then maybe you could just comment on what the expected shelf life is going to be for Anaphylm versus neffy? And any potential temperature requirements?

    好的。很好。那也許你們可以評論一下,Anaphylm 相較於 neffy,預期的保存期限(shelf life)會是多久?以及是否有任何潛在的溫度要求?

  • And then just on 108 regarding the Phase 2a in alopecia areata, how confident are you the FDA will be aligned on that study design in your pre-NDA meeting, both in terms of doses and endpoints that you're looking at? Thanks.

    另外,關於 108 在斑禿(alopecia areata)的 2a 期,你們對 FDA 在 pre-NDA 會議上會就該研究設計達成一致有多大把握——包括你們考量的劑量與終點?謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. Thanks, Gary. So we understand shelf life is an important component for patients and caregivers in this space. And shelf life can mean different things to different people, right? So when we refer to it on calls like this as life sciences experts on our side and your side, we're typically referring to the temperature at which you can store the product, right? But we think when you look at what's important to patients and caregivers, it's the ability in the real world to have a product that can go through all of the daily changes of their lives and still work, right? So our focus is on that way of thinking around shelf life. And while we haven't stated what our excursion data and our shelf-life data will look like, we absolutely are planning on making that robust and something that meets the needs of patients. In terms of alopecia areata, I will let Carl give you his view.

    是的。謝謝,Gary。我們理解在這個領域,保存期限對病患與照護者而言是重要組成。而且保存期限對不同的人可能代表不同的意思,對吧?因此當我們在像這樣的電話會議中,以你我雙方的生命科學專業人士角度提到保存期限時,通常指的是產品可儲存的溫度,對吧?但我們認為,從病患與照護者真正重視的角度來看,是在真實世界中,產品能夠經歷他們日常生活中的各種溫度變化,仍然能有效運作,對吧?所以我們的重點是以這種方式來思考保存期限。雖然我們尚未公布我們的溫度偏離(excursion)資料與保存期限資料會呈現什麼樣貌,但我們絕對計畫讓它足夠扎實,並能滿足病患需求。至於斑禿(alopecia areata),我讓 Carl 來分享他的看法。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Sure. Thanks for the question. And we really did rely heavily on the published data from the Olumiant the BRAVE-1, BRAVE-2 study, where they conducted regression fitting for those data really showing that there's a strong cohort of early responders. And we're using that as our biomarker. I suspect that FDA would view that appropriately as a reasonable endpoint given that these are data extracted and published from the recently approved drug for this indication, but just leveraging their analysis for our needs in an earlier Phase 2 study. So I do think this will be well received, but we'll have to wait for their responses.

    當然。謝謝你的問題。我們確實高度依賴已發表的 Olumiant 之 BRAVE-1、BRAVE-2 研究資料;他們對那些資料做了迴歸擬合(regression fitting),清楚顯示存在一個強勁的早期反應者(early responders)族群。而我們將其作為我們的生物標記(biomarker)。我猜 FDA 會適當地將其視為合理的終點,因為這些資料是從近期獲准用於此適應症的藥物中擷取並發表的,只是我們把他們的分析方法用來滿足我們在較早期 2 期研究中的需求。所以我確實認為這會被良好接受,但我們仍需等待他們的回覆。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Okay. And then if you start that Phase 2a in, was it going to be the second quarter of next year? Just how long to get the data? I know you said before that the overall timeline -- longer-term timeline is intact, but just -- maybe just comment on the Phase 2a specifically?

    好的。那如果你們在——是明年第二季啟動那個 2a 期嗎?大概需要多久才能拿到資料?我知道你們之前說整體時程——長期時程仍維持不變,但——也許請特別評論一下 2a 期?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • So we haven't given guidance yet on when we think the conclusion of that study will be. But Carl maybe you could just give some high-level thoughts around how you would think about it generally.

    我們目前還沒有就我們認為該研究何時結束提供指引。但 Carl,也許你可以從較高層次分享一下,你一般會如何看待這件事。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yeah. So we're looking to have as an adaptive study, an interim look at 12 weeks. Presumably, we'll be able to move forward, then we would have a 24-week readout. But if you add that all up, I would obviously think that we're going to be somewhere a little bit north of six months.

    是的。我們打算把它設計成一個適應性研究(adaptive study),在第 12 週做一次期中檢視(interim look)。推測我們將能夠繼續往前推進,接著會在第 24 週有一次讀出(readout)。但把這些加總起來,我顯然會認為我們大概會落在略高於六個月的時間。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Okay, great. Thanks, guys.

    好的,很棒。謝謝,各位。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • James Molloy, Alliance Global Partners.

    James Molloy,Alliance Global Partners。

  • James Molloy - Analyst

    James Molloy - Analyst

  • Hey, guys. Thanks for taking my questions. Just a couple of quick ones. I know that you touched upon whether or not you going to make a decision on partner and a self-launching based on what's best. When do you think you've come to that decision? Is that something that happens post hopeful approval next year? Or what are the deciding factors for self-launch versus partner?

    嗨,各位。謝謝讓我提問。我只有幾個簡短的問題。我知道你們提到會基於什麼最有利來決定要找合作夥伴或自行上市。你們認為何時會做出這個決定?會是在明年(希望)獲批之後才發生嗎?或者,自行上市與合作夥伴之間的決定因素是什麼?

  • And then on the AQST-108, what is a post-Phase 2a/2b trial timelines look like? I mean, I know that 2028 is the expected launch. Will you walk us through how you get to that, please?

    另外關於 AQST-108,Phase 2a/2b 之後的試驗時程會是什麼樣子?我的意思是,我知道 2028 年是預期上市時間。可以請你們帶我們走一遍如何走到那一步嗎?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. And good morning, Jim. In terms of partner versus self-launch, my philosophy for lack of a better word, you should never look at the universe as black and white as it's one or the other. So as we're building this company, as you've seen as we hit the milestones that we've put out ahead of us, we're always interacting with the community -- the life sciences community around us. When there are opportunities that enhance our ability to grow, enhance our ability to get to more patients, we'll take those opportunities. When those opportunities are not there, we'll do it ourselves. So we don't look at it as a black and white by the state. We either have to have a partner or by the state, we have to self-launch. It is a continuum.

    當然。早安,Jim。就合作夥伴與自行上市而言,我的理念(姑且這麼說)是,你不應該把世界看成非黑即白、只能二選一。因此,在我們打造這家公司、如你所見我們達成先前提出的里程碑的同時,我們一直都在與周遭的社群——生命科學社群——互動。當有機會能提升我們成長能力、提升我們觸及更多病患的能力時,我們就會把握那些機會。當那些機會不存在時,我們就自己做。所以我們不把它視為一個非黑即白的狀態。不是說在某種狀態下我們一定得有合作夥伴,或在某種狀態下我們一定得自行上市。這是一個連續光譜。

  • And what I think we're very good at, as a management team, is making sure that we stay focused on growing rather than on specific moments and time around partners versus self-launch. On 108, I think this gets back to the question Gary asked before. We are -- as you'll see from the materials, we are planning on starting the Phase 2a in the second quarter of next year. As I said before, we haven't given specific guidance on when that would conclude.

    而我認為我們管理團隊很擅長的一點,是確保我們把焦點放在成長上,而不是把焦點放在某個特定時點、去糾結合作夥伴或自行上市。至於 108,我想這回到 Gary 先前問的問題。我們——如你們從資料中會看到——計畫在明年第二季啟動 Phase 2a。如我先前所說,我們尚未就何時結束提供具體指引。

  • Carl gave a high-level view that perhaps it's a six-month-ish timeframe. And our plan obviously would be after that, typically, there would be a Phase 2b. And then after that, we would do our Phase 3 as we get further along, we can talk about (technical difficulty) of the Phase 2b into Phase 3 and so on. But all of that, we believe, can be done in a reasonable timeline for launch in 2028.

    Carl 提供了一個高層次的看法,可能大約是六個月左右的時間。而我們的計畫顯然是在那之後,通常會進入 Phase 2b。再之後,隨著我們進一步推進,我們會進行 Phase 3;屆時我們也可以再談 Phase 2b 銜接到 Phase 3 等等的(技術性細節)。但我們相信,所有這些都能在合理的時程內完成,以在 2028 年上市。

  • James Molloy - Analyst

    James Molloy - Analyst

  • Okay. Just a quick follow-up on that. Because I'm looking at the timeline you guys present from last month or the other month, the Phase 2a Q3 '25, the Phase 2b -- I'm sorry, Phase 2a Q2 '25, Phase 2b Q3 '25, which seemed to suppose a three-month timeline. Should we think that maybe that it's more likely that's a little longer than that for, say, a fourth quarter [ultimately] (inaudible)

    好的。就這點再快速追問一下。因為我在看你們上個月或前個月提供的時程,你們寫 Phase 2a 是 2025 年第三季,Phase 2b——抱歉,Phase 2a 是 2025 年第二季,Phase 2b 是 2025 年第三季,看起來假設只有三個月的時程。我們是否應該認為更可能會比那更久一些,例如到第四季[最終](聽不清)

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. I would focus on as Carl alluded to in our Investor Day and some of the discussions we had publicly since then, we are -- and actually, I think he mentioned it today, we are contemplating having adaptive design to our study. So what that would allow us to do is get some of that additional information that would come from a Phase 2b as we go, which actually I believe there's a slide in our Investor Day presentation that would lay out that continuum from Phase 2a to Phase 2b.

    是的。我會把重點放在 Carl 在我們投資人日以及此後一些公開討論中所提到的——其實我想他今天也提到了——我們正在考慮在研究中採用適應性設計。這將使我們能在進行過程中取得原本會來自 Phase 2b 的一些額外資訊;而我相信在我們投資人日簡報中有一張投影片,會把從 Phase 2a 到 Phase 2b 的那個連續光譜呈現出來。

  • James Molloy - Analyst

    James Molloy - Analyst

  • Great. Thank you very much for the questions.

    很好。非常感謝回答我的問題。

  • Operator

    Operator

  • Thank you. I would now like to turn the call back over to Dan Barber for any closing remarks.

    謝謝。我現在想把電話交回給 Dan Barber,請他做任何結語。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thank you, Josh. Well, thank you to everyone for the time this morning. I just want to reiterate the excitement we have about the moment we're in for this company. We believe we have built value across several different areas, and we're focused on continuing to hit our milestones. And as we continue forward, you'll hear us be disciplined about staying focused on those milestones. With that, we appreciate your time, and we will talk to you soon.

    謝謝你,Josh。也謝謝今天早上撥冗參與的各位。我想再次強調,我們對公司目前所處的這個時刻感到非常振奮。我們相信已在數個不同領域建立了價值,而我們的重點是持續達成我們的里程碑。隨著我們繼續向前,你們會聽到我們以紀律性方式,持續把焦點放在這些里程碑上。最後,感謝各位的時間,我們很快再與各位交流。

  • Operator

    Operator

  • Thank you. This concludes the conference. Thank you for your participation. You may now disconnect.

    謝謝。本次會議到此結束。感謝各位的參與。您現在可以掛線。